Sexual assault by friend left me feeling 'betrayed'
Bryony Piggin, 20, waived her right to anonymity and told the BBC she felt "betrayed" by her former best friend.
She spoke out after Stefan Nikolic, 20, of Coast Road, Bacton, in Norfolk, was found guilty of assault by penetration.
On Friday, Recorder Simon Levene sentenced him to two years in prison, suspended for 24 months, and told him he had "misread" the situation.
Describing her friendship with Nikolic before the attack, Ms Piggin said: "We were inseparable."
The pair had been on a night out with friends in Norwich when the assault happened in April 2023.
The court heard that she had agreed Nikolic could stay at her home in the city, but when she woke up, he was assaulting her.
"It was incomprehensible that my best friend would do something like that to me," she said.
Ms Piggin, who is now unable to work due to her mental health, said the assault left her with a sense of "confusion, betrayal and sadness".
She said she could not believe her former friend "abused" the trust she gave him.
The attack on 29 April 2023, has left Ms Piggin with anxiety issues and led to her dropping out of her Open University course.
"I avoid leaving the house... Trauma makes it impossible to carry on."
Nikolic denied assault by penetration, arguing he had consent, but a jury at Norwich Crown Court found him guilty on 31 March.
Giles Fleming, for the prosecution, said that even two years on, Ms Piggin was still suffering.
Reading from her victim impact statement, he said the "consequences were devastating" and that she was suffering with post traumatic stress disorder (PTSD).
"He didn't just violate my body, he took the person I was.
"Even now, two years on, I can still feel his touch," she said in her statement.
The court heard how Ms Piggin still scrubs herself "raw in the shower" following the sexual assault.
Recorder Levene said the pair had a "warm, affectionate relationship" before the incident.
"You entirely misread the situation," he told Nikolic, adding "I do take into account your lack of maturity."
Nikolic was also handed a five-year restraining order.
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Could This Psychedelic Drug Stock Be a Top Buy for 2026?
Amid a global mental health crisis, the demand for new and effective treatment options is on the rise, particularly in the realm of psychedelic-assisted therapies. Experts believe the psychedelic drug market will grow from $4.1 billion in 2025 to an impressive $7.8 billion by 2030, reflecting a steady compound annual growth rate (CAGR) of 13.7%. As the space gains traction, one small biotech company has caught some investors' attention: Mind Medicine (MNMD), also known as MindMed for short. In its most recent earnings update, MindMed reported solid progress with enrollment across three pivotal Phase 3 trials for its lead candidate, MM120, a refined version of recreational drug lysergide d-tartrate (LSD) currently being studied for generalized anxiety disorder (GAD) and major depressive disorder (MDD). More News from Barchart Supermicro's Earnings Selloff Explained: Should You Buy SMCI Stock Now? Amazon's $36M Bet on Quantum Computing: What Investors Need to Know AMD Stock Slips After Q2 Earnings, But Here's Why It's a Buying Opportunity Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Topline data from these trials is expected in 2026, setting the stage for a potential commercial launch by 2028. And analysts are also beginning to take notice. Oppenheimer, for example, recently expressed optimism based on what it believes could be 'powerful' Phase 3 data next year. So, with clinical milestones approaching, would it be wise to buy the shares of this psychedelic drugmaker? About Mind Medicine Stock MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its most advanced program, MM120, is currently in Phase 3 trials for GAD. Another key candidate, MM402, an MDMA-related compound, is in Phase 1 trials and being studied for its potential to address core symptoms of autism spectrum disorder (ASD). With a pipeline focused on conditions that often lack effective long-term solutions, the company is aiming to bring a fresh approach to mental health treatment. Valued at roughly $747 million by market capitalization, shares of this psychedelic therapy-focused company are gaining traction as investors take note of its advancing clinical pipeline and growing role in mental health innovation. Over the past year, shares have risen 34%, and the rally has only intensified in 2025 with a year-to-date (YTD) gain of 41%. That easily tops the broader S&P 500 Index's ($SPX) 22% gain over the past year and its 8% rise so far this year. Most notably, MindMed has surged 49% in just the last three months, highlighting growing investor interest. A Look Inside Mind Medicine's Q2 Earnings MindMed's fiscal 2025 second-quarter earnings, released on July 31, painted a mixed picture as the company deepens its push into late-stage development. The pre-revenue biotech firm posted a loss of $0.50 per share, widening from a loss of $0.26 a year ago and missing Wall Street's forecast of a $0.38 loss per share. The shortfall was driven by a sharp increase in research and development expenses, which surged 103.5% year-over-year (YOY) to $29.8 million, primarily due to the advancement of the MM120 program. While the company is investing heavily in advancing the MM120 program, one area of concern is the limited insight into the treatment's long-term effectiveness. So far, Phase 2 data only tracks results up to 12 weeks, leaving questions about how durable the benefits may be over an extended period. That said, MindMed's financial position remains strong. As of June 30, the company reported $237.9 million in cash, cash equivalents, and investments, enough to support operations into 2027 and beyond the first topline readout from its Phase 3 MM120 ODT trial. Meanwhile, clinical progress continues to move forward. MindMed remains on schedule with enrollment across three pivotal Phase 3 trials — Voyage, Panorama, and Emerge — which are focused on MM120 ODT for the treatment of GAD and MDD. These studies are designed to assess the efficacy of MM120 ODT as a standalone treatment, without the need for psychotherapy. The company expects topline data from its Phase 3 Voyage trial in the first half of 2026, followed by Panorama and Emerge in the second half. What Do Analysts Think About Mind Medicine Stock While investors' reaction to the company's Q2 results was somewhat underwhelming, sentiment took a sharp positive turn on Aug. 4 when shares jumped nearly 11% following an upgrade from Oppenheimer. Analyst Jay Olson lifted the psychedelic drug developer to an 'Outperform' rating and set a 12- to 18-month price target of $25, citing the promising potential of its lead candidate, MM120. Olson highlighted MM120's 'unique clinical profile,' describing it as a pharmaceutical form of LSD that delivers a less intense but longer-lasting psychedelic experience compared to other approaches. The analyst also emphasized the drug's potential in treating neuropsychiatric conditions like GAD and MDD. Backing his optimism, Olson noted encouraging Phase 2 trial data for MM120 in GAD, which showed favorable remission rates as well as a favorable safety and tolerability profile over a 12-week period. In his view, MindMed remains undervalued and is strategically positioned ahead of its anticipated Phase 3 readout Overall, MNMD stock has earned a resounding vote of confidence on Wall Street, carrying a consensus rating of 'Strong Buy.' Of the 11 analysts covering the stock, a majority of 10 analysts recommend a "Strong Buy" while the remaining one gives a 'Moderate Buy' rating. The average analyst price target of $25 indicates significant upside potential of 157% from the current price levels. Final Thoughts While MindMed's journey comes with the usual biotech risks — especially given its pre-revenue status, rising R&D costs, and questions around the long-term durability of MM120's effects — the company's progress in late-stage trials, strong financial position, and growing confidence from Wall Street paint an encouraging picture. For investors comfortable with biotech volatility and looking to gain exposure to the emerging psychedelic therapy space, MindMed could be a promising buy ahead of its anticipated Phase 3 milestones in 2026. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Three brothers jailed after 21-year-old murdered following car crash 'dispute'
Three brothers from Normacot have been jailed today after a 21-year-old man was senselessly killed following a petty dispute over a car crash. Tayyab Hussain, 27, Ezaan Hussain, 22, and Tuheed Hussain, 24, were sentenced at Loughborough Crown Court. The victim - Thalepo Jali, of Stafford - was driving his girlfriend's Volkswagen T-Roc on July 20 last year, when he became involved in a collision with a Honda Civic, driven by Tuheed Hussain. The following day, on July 21, Tuheed and Ezaan vandalised Jali's car, smashing up the windows. Later that evening, CCTV captured Jali running into an alleyway in Normacot, which ran between Hamilton Road and Buccleuch Road, at 11.47pm. Four seconds later, Tayyab and Ezaan Hussain jumped out of a car driven by Tuheed and chased Jali into the alleyway. READ MORE: Live updates as police dog out during 'serious disorder' in North Staffordshire READ MORE: Police called in as two-miles of North Staffordshire canal 'drained' The cold-hearted pair cornered Jali before stabbing him multiple times. Tayyab and Ezaan then ditched the scene, before being picked up by Tuheed on Hamilton Road. Jali was discovered lying in the alley shortly afterwards at 12.30am on Sunday, July 22. Sadly there was nothing paramedics could do, and he died on the scene at around 1.10am. Attackers Tayyab and Ezaan Hussain pleaded guilty to murder on July 7 and July 9, 2025 respectively. Driver Tuheed Hussain was found guilty of manslaughter by a jury on Monday (August 4). Tayyab was sentenced to 21 years and 351 days' imprisonment, Ezaan was jailed for 20 years and 353 days and Tuheed was sentenced to 11 years' imprisonment. Jali's heart-broken family have shared their grief in a statement shared with Staffordshire Police. They said: "We love and miss Thapelo and his death has left an unmeasurable void in the lives of us who love him so dearly. "When the officers came to tell us about Thapelo's death, their words changed our lives forever. That morning, little did we know that our lives were now changed, beyond anything that we could ever imagine. 'The stark reality of Thapelo's death was something that quickly absorbed our family, devastating us completely, as the days, weeks and months have passed. 'One young life was taken in the most tragic and cruel set of circumstances, yet many lives have been ruined through the ripples of devastation caused by these dreadful events. 'I hope that in some small way, my words help to discourage the epidemic of knife crime that has taken my son from his family at such a young age. I want for no other family to have to experience the level of pain that we have, and continue, to endure.' Detective Superintendent Cheryl Hannan said: 'Our thoughts remain with Thapelo's family and friends. 'This was a brutal and calculated attack. This highlights the tragic consequences of carrying a knife and conflict between groups.' Get all the latest news from court here
Yahoo
an hour ago
- Yahoo
Orpington man killed moped rider in deliberate road rage crash
An Orpington man who deliberately drove into a moped rider, killing him in a road rage incident, has been jailed for 13 years. Neil Sullingston, 53, was sentenced on August 1 after being found guilty of manslaughter earlier this week. He drove his car into 36-year-old Wayne Wigley in Esher, Surrey, on the morning of July 1, 2024. Sullingston, of Orpington, was driving to work in his white Seat Ibiza along the A244 when he noticed Mr Wigley riding a moped behind him. The two men had previously been involved in road rage incidents on May 16 and June 5, which Sullingston had reported to police. READ MORE: At around 6.19am on July 1, dashcam and CCTV footage showed Mr Wigley throwing a rock at Sullingston's car, smashing the rear window. Mr Wigley then entered the right filter lane near the junction with Milbourne Lane. Sullingston followed in close pursuit before deliberately driving into the back of the scooter without braking or swerving. The impact threw Mr Wigley from the moped, severing his right lower leg and causing catastrophic internal injuries. Members of the public, including an off-duty police officer, a paramedic and a firefighter tried to help but Mr Wigley was pronounced dead at the scene. Detective Chief Inspector Natalie Pearce, the senior investigating officer, said: 'Our thoughts are with the family and friends of Wayne Wigley following his death in July last year. 'Sadly, on the day in question, the road rage escalated with fatal consequences. Sullingston deliberately drove at Mr Wigley, intending to cause harm, which ultimately resulted in his death. 'His actions that day were inexcusable and unforgivable, and the fact that he has been imprisoned today for 13 years after being found guilty of manslaughter has ensured he has been brought to justice for the loss of another man's life.' Mr Wigley's family said: 'Wayne is dearly missed by his seven children, his mum, dad, partner, sister and all his friends. He was well loved by all and would do anything for anyone. 'He was strong-minded, loyal, generous and funny. A keen fisherman, a skilled banger racer and a gifted car mechanic. 'We would like to thank all our family and friends for their support, which has helped us through the horror of what has happened.'
